Soft tissue sarcoma refers to a broad term of cancers that stem from soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). These cancers can develop anywhere in the body but are most found in the arms, legs, chest and abdomen.  Around 43% of soft tissue tumours start in the arms or legs. Most of the others are found in the head and neck or inside other organs, including the liver, lung, kidney, uterus, breast, gastrointestinal tract or the abdominal cavity.

This report provides the current incident population for soft tissue sarcoma across 27 Major Markets (USA, France, Germany, Italy, Spain, Brazil, Mexico, Argentina, Turkey, India, UK, Netherlands, Belgium, Switzerland, Austria, Denmark, Sweden, Norway, Finland, Russia, Poland, Australia, Ireland, Iceland, Luxembourg, Japan, S. Korea and China), split by gender and 5-yr age cohort. Alongside the incidence, the report also contains background literature, a disease overview, risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan Analysis, several of the main symptoms and comorbidities of soft tissue sarcoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across a 10-year forecast (2019-2029) snapshot.

Diseases associated with soft tissue sarcoma:

  • Hereditary retinoblastoma
  • Li Fraumeni syndrome
  • Neurofibromatosis
  • Werner syndrome

The type of cell that develops the genetic mutation determines what type of soft tissue sarcoma you have.

The report is built using data and information sourced from out proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiological studies. All sources used to generate the data and analysis have been identified in this report.

Reason to buy:

  • Able to quantify patient populations in global soft tissue sarcoma markets to target development of future products, pricing strategies and launch plans
  • Gain a further insight into the prevalence of the subdivided subtypes of soft tissue sarcoma and identify patient segments with a high potential
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
  • Provide a level of understanding on the impact from specific co-morbid conditions on soft tissue sarcoma’s incident population
  • Gain an understanding of the specific markets that have the largest number of soft tissue sarcoma patients